drugset / Trial / NCT02426021
Phase 1 Single Subcutaneous Dose Study of MLN1202
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of the study is to investigate the safety, pharmacokinetics, and pharmacodynamic effect of a single dose of MLN1202 in healthy Japanese male adults.
Timeline
- Start
- 2015-04
- Primary completion
- 2015-11
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PLOZALIZUMAB | Monoclonal antibody | 75 mg | Subcutaneous |
| Subject | PLOZALIZUMAB | Monoclonal antibody | 105 mg | Subcutaneous |
| Subject | PLOZALIZUMAB | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | PLOZALIZUMAB | Monoclonal antibody | 450 mg | Subcutaneous |
Indications
No indication recorded.